Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Reportable Segment Net Revenues and Loss

The Company's reportable segment net revenues, significant segment expenses and consolidated profit (loss) for the years ended December 31, 2024 and 2023, consisted of the following:

	Year Ended December 31,
	2024			2023
Revenues:
Grant Revenue	$	20,581		$	7,046
Collaboration revenue - related party		27,025			95,802
Collaboration revenue		371			933
Total revenues		47,977			103,781
Less:
Tebipenem HBr		60,502			16,695
SPR720		16,626			13,031
SPR206		570			3,240
Research and development personnel related (including share-based compensation)		14,111			13,788
Facility related and other, research and development		4,948			4,686
General and administrative personnel related (including share-based compensation)		13,188			15,324
Professional and consultant fees		8,198			8,151
Facility related and other, general and administrative		2,318			2,079
Other segment items*		817			5,320
Interest income		(4,735	)		(3,937	)
Income tax expense		-			2,598
Consolidated profit (loss)	$	(68,566	)	$	22,806

*Other segment items include restructuring charges (see Note 9), impairment of long-term asset and other income, net.